Innehållet på denna webbplats är endast avsett för veterinärer eller andra professionella inom djurhälsovård.
Genom att använda denna webbplats accepterar du ovanstående.
Intervacc’s distribution partner Dechra launches Strangvac in Spain, Portugal and Slovenia
Intervacc AB (publ) announces today that its European distribution partner, Dechra Pharmaceuticals PLC (“Dechra”), is launching Strangvac® in Spain, Portugal and Slovenia. Vials of the vaccine against the highly contagious bacterial equine disease strangles are...Report from Annual General Meeting in Intervacc
Intervacc AB (publ) has held its Annual General Meeting (”AGM”) on Wednesday 14 May 2025, at which the following resolutions were made. Adoption of the income statement and balance sheet The AGM adopted the Board of Directors’ submitted income statement and balance...Interim report January – March 2025
The Group in summary 01/01/25 01/01/24 01/01/24 -31/03/25 -31/03/24 -31/12/24 Net sales 4 574 2 394 11 787 Operating result -13 537 -17 979 -77 277 Result after financial items -13 172 -17...Intervacc’s distribution partner Dechra launches Strangvac in Finland
Intervacc AB (publ) announces today that its distribution partner, Dechra Pharmaceuticals PLC (”Dechra”), will launch Strangvac® in Finland and vaccine vials are expected to be available for delivery shortly. This launch is the result of an extended...Notice of Annual General Meeting in Intervacc AB (publ)
The shareholders of Intervacc AB (publ), reg. no. 556238-1748 (the “Company”), are hereby invited to the Annual General Meeting (“AGM”) to be held on Wednesday 14 May 2025 at 3.00 p.m. at Cirio Advokatbyrå, Biblioteksgatan 9, in Stockholm. The Board of Directors has...Nyhetstjänster
